Research and Development Investment: Viatris Inc. vs Perrigo Company plc

A Decade of Innovation: Viatris Inc. vs Perrigo Company plc

In the ever-evolving pharmaceutical industry, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Viatris Inc. and Perrigo Company plc have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, Viatris Inc. consistently outpaced Perrigo, investing nearly 4.5 times more in R&D by 2023. This strategic focus on innovation is evident as Viatris increased its R&D spending by approximately 56% over the period, peaking in 2023. In contrast, Perrigo's R&D investment saw a decline of about 20%, reflecting a more conservative approach. These trends highlight Viatris's commitment to pioneering new solutions, while Perrigo may be focusing on optimizing existing products. As the pharmaceutical landscape continues to shift, these investment patterns could significantly influence each company's future market position.